Mucosally administered Lactobacillus surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) Induce broadly protective immune responses against divergent influenza subtypes

Veterinary Microbiology

Volumn 179, Issue 3-4, 2015, Pages 250-263

  Li, Rui ^a   Chowdhury, Mohammed Y E ^a,c   Kim, Jae Hoon ^a   Kim, Tae Hwan ^a   Pathinayake, Prabuddha ^a   Koo, Wan Seo ^a   Park, Min Eun ^d   Yoon, Ji Eun ^d   Roh, Jong Bok ^b   Hong, Seung Pyo ^b   Sung, Moon Hee ^b   Lee, Jong Soo ^a   Kim, Chul Joong ^a  

^a Chungnam National University   (South Korea)

^b Bioleaders Corporation   (South Korea)

^c Chittagong Government Veterinary College   (Bangladesh)

^d Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

Author keywords

Influenza; Mucosal immunity; Surface display

Indexed keywords

CHOLERA TOXIN; CHOLERA TOXIN SUBUNIT A1; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; PROTEIN M2; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; MEMBRANE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA; LACTOBACILLUS CASEI; MOUSE; NONHUMAN; PLASMID; PROTEIN EXPRESSION; ANIMAL; BAGG ALBINO MOUSE; CROSS PROTECTION; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA A VIRUS (H5N1); INFLUENZA A VIRUS (H5N2); INFLUENZA A VIRUS (H9N2); INTRANASAL DRUG ADMINISTRATION; LACTOBACILLUS; METABOLISM; ORTHOMYXOVIRIDAE INFECTIONS; PRECLINICAL STUDY; SOUTH KOREA;

ANIMALIA; LACTOBACILLUS; LACTOBACILLUS CASEI; MUS; ORTHOMYXOVIRIDAE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, SURFACE; CHOLERA TOXIN; CROSS PROTECTION; DRUG EVALUATION, PRECLINICAL; IMMUNITY, CELLULAR; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H5N2 SUBTYPE; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA VACCINES; INTERLEUKIN-4; LACTOBACILLUS; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; REPUBLIC OF KOREA;

EID: 84938747067     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2015.07.020     Document Type: Article

References (74)

1. Agren L., Lowenadler B., Lycke N. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Immunol. Cell Biol. 1998, 76:280-287.
2. Agren L., Sverremark E., Ekman L., Schon K., Lowenadler B., Fernandez C., Lycke N. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects. J. Immunol. 2000, 164:6276-6286.
3. Agren L.C., Ekman L., Lowenadler B., Lycke N.Y. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 1997, 158:3936-3946.
4. Agren L.C., Ekman L., Lowenadler B., Nedrud J.G., Lycke N.Y. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 1999, 162:2432-2440.
5. EI Bakkouri K., Descamps F., Filette M.D., Smet A., Festjens E., et al. Universal Vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 2011, 186:1022-1031.
6. Bommakanti G., Citron M.P., Hepler R.W., Callahan C., Heidecker G.J., Najar T.A., Lu X., Joyce J.G., Shiver J.W., Casimiro D.R., ter Meulen J., Liang X., Varadarajan R. Design of an HA2-based E. coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13701-13706.
7. Brisbin J.T., Gong J., Parvizi P., Sharif S. Effects of lactobacilli on cytokine expression by chicken spleen and cecal tonsil cells. Clin. Vaccine Immunol. 2010, CVI 17:1337-1343.
8. Carrat F., Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007, 25:6852-6862.
9. Chowdhury M.Y., Li R., Kim J.H., Park M.E., Kim T.H., Pathinayake P., Weeratunga P., Song M.K., Son H.Y., Hong S.P., Sung M.H., Lee J.S., Kim C.J. Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice. PloS One 2014, 9:e94051.
10. Chowdhury M.Y., Seo S.K., Moon H.J., Talactac M.R., Kim J.H., Park M.E., Son H.Y., Lee J.S., Kim C.J. Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice. Virol. J. 2014, 11:21.
11. Christensen H.R., Frokiaer H., Pestka J.J. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J. Immunol. 2002, 168:171-178.
12. De Filette M., Ramne A., Birkett A., Lycke N., Lowenadler B., Min Jou W., Saelens X., Fiers W. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 2006, 24:544-551.
13. T.D'Mello, L. Brammer, L. Blanton, K. Kniss, S. Smith, D. Mustaquim, C. Steffens, R. Dhara, J. Cohen, S.S. Chaves, 2015. Update: influenza activity-United States, september 28, 2014-february 21, 2015. MMWR. Morbidity and mortality weekly report 64, 206-212.
14. Eliasson D.G., El Bakkouri K., Schon K., Ramne A., Festjens E., Lowenadler B., Fiers W., Saelens X., Lycke N. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 2008, 26:1243-1252.
15. Ellebedy A.H., Ducatez M.F., Duan S., Stigger-Rosser E., Rubrum A.M., Govorkova E.A., Webster R.G., Webby R.J. Impact of prior seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferrets. Vaccine 2011, 29:3335-3339.
16. Eriksson A.M., Schon K.M., Lycke N.Y. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J. Immunol. 2004, 173:3310-3319.
17. Frank W., Gartlan K.H., Harandi A.M., Brinckmann S.A., Coccia M., Hillson W.R., Kok W.L., Cole S.P., Ho L., Lambe T., Puthia M., Svanborg C., Scherer E.M., Krashias G., Williams A., Blattman J.N., Greenberg P.D., Flavell R.A., Moghaddam A.E., Sheppard N.C. Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat. Biotechnol. 2012, 30:883-888.
18. Friedman R.S., Frankel F.R., Xu Z., Lieberman J. Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens. J. Virol. 2000, 74:9987-9993.
19. Fu T.M., Freed D.C., Horton M.S., Fan J., Citron M.P., et al. Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology 2009, 385:218-226.
20. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003, 21:1776-1779.
21. Gocnik M., Fislova T., Mucha V., Sladkova T., Russ G., Kostolansky F., Vareckova E. Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection. J. Gen. Virol. 2008, 89:958-967.
22. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., Tang J., McDonald W., Song L., Evans R.K., Umlauf S., Tussey L., Powell T.J. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
23. Ito T., Gorman O.T., Kawaoka Y., Bean W.J., Webster R.G. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J. Virol. 1991, 65:5491-5498.
24. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 2004, 172:5598-5605.
25. Kim E.H., Lee J.H., Pascua P.N., Song M.S., Baek Y.H., Kwon H.I., Park S.J., Lim G.J., Decano A., Chowdhury M.Y., Seo S.K., Song M.K., Kim C.J., Choi Y.K. Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza A virus in mice. Virol. J. 2013, 10:104.
26. Kiyono H., Fukuyama S. NALT-versus Peyer's-patch-mediated mucosal immunity. Nat. Rev. Immunol. 2004, 4:699-710.
27. Lalor P.A., Webby R.J., Morrow J., Rusalov D., Kaslow D.C., Rolland A., Smith L.R. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J. Infect. Dis. 2008, 197:1643-1652.
28. Lamb R.A., Zebedee S.L., Richardson C.D. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985, 40:627-633.
29. Lee J.S., Chowdhury M.Y., Moon H.J., Choi Y.K., Talactac M.R., Kim J.H., Park M.E., Son H.Y., Shin K.S., Kim C.J. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response. J. Virol. Methods 2013, 194:280-288.
30. Lee J.S., Poo H., Han D.P., Hong S.P., Kim K., Cho M.W., Kim E., Sung M.H., Kim C.J. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J. Virol. 2006, 80:4079-4087.
31. Lee J.S., Shin K.S., Pan J.G., Kim C.J. Surface-displayed viral antigens on Salmonella carrier vaccine. Nat. Biotechnol. 2000, 18:645-648.
32. Lee M.H., Roussel Y., Wilks M., Tabaqchali S. Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine 2001, 19:3927-3935.
33. Liu W., Zou P., Ding J., Lu Y., Chen Y.H. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect./Institut Pasteur 2005, 7:171-177.
34. Lycke N., Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 1986, 59:301-308.
35. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 2012, 12:592-605.
36. Mohamadzadeh M., Olson S., Kalina W.V., Ruthel G., Demmin G.L., Warfield K.L., Bavari S., Klaenhammer T.R. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:2880-2885.
37. Mozdzanowska K., Zharikova D., Cudic M., Otvos L., Gerhard W. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol. J. 2007, 4:118.
38. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., Spyr C., Steffen R. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. New Engl. J. Med. 2004, 350:896-903.
39. Nichol K.L., Mendelman P.M., Mallon K.P., Jackson L.A., Gorse G.J., Belshe R.B., Glezen W.P., Wittes J. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA: J. Am. Med. Assoc. 1999, 282:137-144.
40. O'Hagan D.T., Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2003, 2:727-735.
41. Okuno Y., Matsumoto K., Isegawa Y., Ueda S. Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J. Virol. 1994, 68:517-520.
42. Osterholm M.T. Preparing for the next pandemic. New Engl. J. Med. 2005, 352:1839-1842. The.
43. Quan F.S., Vunnava A., Compans R.W., Kang S.M. Virus-like particle vaccine protects against 2009H1N1 pandemic influenza virus in mice. PloS One 2010, 5:e9161.
44. Reed S.G., Orr M.T., Fox C.B. Key roles of adjuvants in modern vaccines. Nat. Med. 2013, 19:1597-1608.
45. Rose M.A., Zielen S., Baumann U. Mucosal immunity and nasal influenza vaccination. Exp. Rev. Vaccines 2012, 11(5):595-607. 10.1586/erv.12.31.
46. Robinson K., Chamberlain L.M., Lopez M.C., Rush C.M., Marcotte H., Le Page R.W., Wells J.M. Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C. Infect. Immun. 2004, 72:2753-2761.
47. Shata M.T., Hone D.M. Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity. J. Virol. 2001, 75:9665-9670.
48. Shata M.T., Reitz M.S., DeVico A.L., Lewis G.K., Hone D.M. Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine 2001, 20:623-629.
49. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 2000, 69:531-569.
50. Smirnov Y.A., Lipatov A.S., Gitelman A.K., Claas E.C., Osterhaus A.D. Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region. Arch. Virol. 2000, 145:1733-1741.
51. Song J.M., Wang B.Z., Park K.M., Van Rooijen N., Quan F.S., et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 2011, 6:e14538.
52. Stevens J., Donis R.O. Influenza virus hemagglutinin-structural studies and their implications for the development of therapeutic approaches. Infect. Disord. Drug Targets 2007, 7:329-335.
53. Stoeker L., Nordone S., Gunderson S., Zhang L., Kajikawa A., LaVoy A., Miller M., Klaenhammer T.R., Dean G.A. Assessment of Lactobacillus gasseri as a candidate oral vaccine vector. Clin. Vaccine Immunol. 2011, 18:1834-1844.
54. Sun H.X., Ye Y.P., Pan H.J., Pan Y.J. Adjuvant effect of Panax notoginseng saponins on the immune responses to ovalbumin in mice. Vaccine 2004, 22:3882-3889.
55. Thaiwong N., Thaiudom S., Haltrich D., Yamabhai M. Production of recombinant β-galactosidase in Lactobacillus plantarum, using a pSIP-based food-grade expression system. Adv. Mater. Res. 2014, 1518-1523.
56. Tripathi P., Beaussart A., Alsteens D., Dupres V., Claes I., Von Ossowski I., De Vos W.M., Palva A., Lebeer S., Vanderleyden J. Adhesion and nanomechanics of pili from the probiotic Lactobacillus rhamnosus GG. Acs Nano 2013, 7:3685-3697.
57. Vajdy M., Lycke N.Y. Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology 1992, 75:488-492.
58. van Baarlen P., Wells J.M., Kleerebezem M. Regulation of intestinal homeostasis and immunity with probiotic lactobacilli. Trends Immunol. 2013, 34:208-215.
59. van Ginkel F.W., Jackson R.J., Yuki Y., McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 2000, 165:4778-4782.
60. Vareckova E., Mucha V., Wharton S.A., Kostolansky F. Inhibition of fusion activity of influenza A haemagglutinin mediated by HA2-specific monoclonal antibodies. Arch. Virol. 2003, 148:469-486.
61. Viboud C., Miller M., Olson D., Osterholm M., Simonsen L. Preliminary estimates of mortality and years of life lost associated with the 2009 A/H1N1 pandemic in the US and comparison with past influenza seasons. PLoS Curr. 2010, 2:RRN1153.
62. Vintini E., Villena J., Alvarez S., Medina M. Administration of a probiotic associated with nasal vaccination with inactivated Lactococcus lactis-PppA induces effective protection against pneumoccocal infection in young mice. Clin. Exp. Immunol. 2010, 159:351-362.
63. Vogel F.R., Caillet C., Kusters I.C., Haensler J. Emulsion-based adjuvants for influenza vaccines. Exp. Rev. Vaccines 2009, 8:483-492.
64. Wang R., Song A., Levin J., Dennis D., Zhang N.J., et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res. 2008, 80:168-177.
65. Wang Z., Yu Q., Gao J., Yang Q. Mucosal and systemic immune responses induced by recombinant Lactobacillus spp. expressing the hemagglutinin of the avian influenza virus H5N1. Clin. Vaccine Immunol. 2012, 19:174-179.
66. Webby R.J., Webster R.G., Richt J.A. Influenza viruses in animal wildlife populations. Curr. Top. Microbiol. Immunol. 2007, 315:67-83.
67. Wiley D.C., Skehel J.J. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem. 1987, 56:365-394.
68. Wilson I.A., Cox N.J. Structural basis of immune recognition of influenza virus hemagglutinin. Annu. Rev. Immunol. 1990, 8:737-771.
69. Wilson I.A., Skehel J.J., Wiley D.C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 1981, 289:366-373.
70. Wu F., Yuan X.Y., Huang W.S., Chen Y.H. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine. Vaccine 2009, 27:6095-6101.
71. Zhao G., Du L., Xiao W., Sun S., Lin Y., Chen M., Kou Z., He Y., Lustigman S., Jiang S., Zheng B.J., Zhou Y. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Vaccine 2010, 28:7233-7240.
72. Zhao G., Lin Y., Du L., Guan J., Sun S., Sui H., Kou Z., Chan C.C., Guo Y., Jiang S., Zheng B.J., Zhou Y. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol. J. 2010, 7:9.
73. Zhao G., Sun S., Du L., Xiao W., Ru Z., Kou Z., Guo Y., Yu H., Jiang S., Lone Y., Zheng B.J., Zhou Y. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 1N1 virus. Virol. J. 2010, 7:151.
74. Zheng L., Wang F., Yang Z., Chen J., Chang H., Chen Z. A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice. BMC Infect. Dis. 2009, 9:17.